Aprea Therapeutics, Inc. (APRE)
NASDAQ: APRE · Real-Time Price · USD
0.7699
+0.0199 (2.65%)
At close: Jul 7, 2026, 4:00 PM EDT
0.7600
-0.0099 (-1.29%)
After-hours: Jul 7, 2026, 5:33 PM EDT
Aprea Therapeutics Revenue
Aprea Therapeutics had revenue of $123.30K in the twelve months ending March 31, 2026, down -90.40% year-over-year. In the year 2025, Aprea Therapeutics had annual revenue of $285.76K, down -80.98%.
Revenue (ttm)
$123.30K
Revenue Growth
-90.40%
P/S Ratio
77.32
Revenue / Employee
$15,412
Employees
8
Market Cap
9.53M
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 285.76K | -1.22M | -80.98% |
| Dec 31, 2024 | 1.50M | 919.35K | 157.63% |
| Dec 31, 2023 | 583.23K | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Immuron | 4.99M |
| Vistagen Therapeutics | 1.27M |
| Can-Fite BioPharma | 405.00K |
| BioRestorative Therapies | 357.87K |
| Jupiter Neurosciences | 40.45K |
| Aspire Biopharma Holdings | 34.56K |
APRE News
- 21 days ago - Aprea Therapeutics Transcript: AGM 2026 - Transcripts
- 5 weeks ago - Aprea Therapeutics Presents Updated Phase 1 Data on WEE1 Inhibitor APR-1051 at ASCO 2026, Demonstrating Early Monotherapy Activity and Manageable Tolerability in Advanced Solid Tumors - GlobeNewsWire
- 7 weeks ago - Aprea Therapeutics price target lowered to $6 from $7 at Wedbush - TheFly
- 7 weeks ago - Aprea Therapeutics reports Q1 EPS (22c) vs. (66c) last year - TheFly
- 7 weeks ago - Aprea Therapeutics Earnings release: Q1 2026 - Filings
- 7 weeks ago - Aprea Therapeutics Quarterly report: Q1 2026 - Filings
- 7 weeks ago - Aprea Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update - GlobeNewsWire
- 2 months ago - Aprea Therapeutics initiated with an Outperform at Oppenheimer - TheFly